Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Journal of Comparative Effectiveness Research
|
October 8, 2020
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
Keith A Betts, Per-Olof Thuresson, Federico Felizzi, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 17, 2023
Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
Shelby Sydnor, Swarnendu Chatterjee, Philip Cooney, et al.
Journal of Medical Economics
|
March 6, 2019
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
Umang Ondhia, H J Conter, Scott Owen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 2, 2022
Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force
William V Padula, Noemi Kreif, David J Vanness, et al.
Clinical Lung Cancer
|
July 19, 2018
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer
Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
March 30, 2012
Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons
João R Gomes, João T Costa, Carlos V Melo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Journal of Comparative Effectiveness Research
|
October 8, 2020
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
Keith A Betts, Per-Olof Thuresson, Federico Felizzi, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 17, 2023
Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
Shelby Sydnor, Swarnendu Chatterjee, Philip Cooney, et al.
Journal of Medical Economics
|
March 6, 2019
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
Umang Ondhia, H J Conter, Scott Owen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 2, 2022
Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force
William V Padula, Noemi Kreif, David J Vanness, et al.
Clinical Lung Cancer
|
July 19, 2018
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer
Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
March 30, 2012
Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons
João R Gomes, João T Costa, Carlos V Melo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.
Page
of 2